Mode
Text Size
Log in / Sign up

Inflammation and fibrosis circuits drive tissue remodeling and neurogenic inflammation in endometriosisFibrosis and Inflammation Link to Endometriosis Pain and Infertility

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the role of the inflammation-fibrosis circuit in driving tissue remodeling and neurogenic inflammation in endometriosis.

This mini review explores the mechanistic links between inflammation and fibrosis in endometriosis. The authors describe a self-maintaining inflammation-fibrosis circuit where cyclic bleeding activates platelets and innate immune cells. This process generates iron-dependent oxidative stress and hypoxia, which sustain signaling pathways including TGF-beta, S1P, Wnt/beta-catenin, PI3K/AKT-ERK, and Notch. These signals promote fibroblast activation, myofibroblast differentiation, and extracellular-matrix deposition.

The resulting stiff matrix can reinforce inflammatory, vascular, and neural programs. This process may stabilize ectopic lesions, promote adhesions, increase tissue tension, and cause neurogenic inflammation. These mechanisms are linked to clinical outcomes such as pain and infertility, though the authors note that fibrosis is not the sole determinant of symptoms and is not a uniform feature across all lesion phenotypes.

Several limitations are noted, including uncertainties regarding cellular lineage, lesion chronology, and outcome attribution. While the review identifies potential pathways for intervention, the authors state that antifibrotic and immunomodulatory approaches currently require mechanism-based clinical validation before they can be integrated into standard care.

How this fits prior evidence

This review extends the immune-fibrotic framework that links endometriosis and adenomyosis to non-hormonal targets. It specifically details the mechanisms of the inflammation-fibrosis circuit, providing a more granular look at how tissue remodeling contributes to pain and infertility. It also aligns with the identification of non-hormonal targets, though it shares the caveat that these mechanisms require further clinical validation before altering current standard treatments.

This review explores how the body reacts to endometriosis. It describes a cycle where monthly bleeding triggers immune cells and creates stress in the tissue. This process leads to fibrosis, which is the formation of stiff, scarred tissue. This scarring can create a cycle that keeps the inflammation going.

This stiff tissue may have several effects on the body. It can cause tissue tension, promote the growth of adhesions, and potentially damage the ovarian cortex. These changes are linked to the chronic pain and fertility challenges many people with endometriosis face. The study notes that while these mechanisms are linked to symptoms, fibrosis is not the only factor involved.

Because these processes are complex, the research is currently focused on understanding the underlying mechanisms. While standard treatments like surgery and hormone therapy are common, these findings suggest that future treatments might focus on reducing scarring and calming the immune response. Patients should discuss these findings with their doctors to understand how they relate to their specific care plan.

What this means for you:
A cycle of inflammation and tissue scarring is linked to pain and infertility in endometriosis.

Common questions

What role does tissue scarring play in endometriosis?

The review describes a cycle where bleeding triggers immune cells and creates oxidative stress. This leads to fibrosis, or the formation of a stiff tissue matrix. This stiff matrix can reinforce inflammation and may contribute to tissue tension and the development of adhesions.

How does this process affect pain and fertility?

The resulting stiff tissue can promote neurogenic inflammation and increase tissue tension. These factors are linked to the chronic pain and infertility often associated with endometriosis. However, the review notes that fibrosis is not the only factor determining these symptoms.

Are there new ways to treat endometriosis based on this research?

Current standards for endometriosis include hormonal and surgical treatments. This research suggests that future approaches might include ways to target fibrosis and the immune system, but these methods still need more clinical testing to be proven effective.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Endometriosis is an estrogen-dependent chronic inflammatory disorder in which ectopic endometrial-like tissue undergoes repeated injury, incomplete resolution, and progressive remodeling. Fibrosis is therefore not merely a terminal scar but an active component of lesion biology. Cyclic bleeding activates platelets and innate immune cells, generates iron-dependent oxidative stress and hypoxia, and sustains transforming growth factor-β, sphingosine-1-phosphate, Wnt/β-catenin, PI3K/AKT–ERK, and Notch-related signals. These cues promote fibroblast activation, myofibroblast differentiation, extracellular-matrix deposition, and epithelial-, endothelial-, mesothelial-, or macrophage-to-mesenchymal plasticity. The resulting stiff matrix can further reinforce inflammatory, vascular, and neural programs, creating a self-maintaining inflammation–fibrosis circuit. Clinically, this circuit may stabilize ectopic lesions, promote adhesions, increase tissue tension and neurogenic inflammation, damage the ovarian cortex, and perturb the peritoneal and eutopic endometrial environments. These effects provide mechanistic links to persistent pain and infertility, although fibrosis is neither the sole determinant of symptoms nor a uniform feature across lesion phenotypes. This Mini Review integrates evidence from experimental models, human pathology, and single-cell studies; identifies uncertainties in cellular lineage, lesion chronology, and outcome attribution; and discusses therapeutic implications. Conventional hormonal and surgical treatment remains central, whereas antifibrotic, immunomodulatory, and complementary approaches require mechanism-based clinical validation. Progress will depend on standardized fibrosis phenotyping, longitudinal and spatial sampling, patient-derived multicellular models, and trials that align biological targets with pain, fertility, and recurrence outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.